GlassScriptPhysician profile
Michael Coty Maddox
NPI 1770216764
$659.07
in general payments reported to CMS, 2019-2025
14 companies · $436 in 2025
The $436 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $58.57 · 2023: $76.06 · 2024: $88.38 · 2025: $436.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $601.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $600.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $141.76 | 2025 | Camzyos |
| Pfizer INC. | $120.78 | 2022-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $86.61 | 2025 | Lifevest |
| United Therapeutics Corporation | $61.68 | 2024-2025 | Tyvaso, Tyvaso |
| Novo Nordisk INC | $58.30 | 2024-2025 | Wegovy, Ozempic, Rybelsus |
| Chiesi USA, INC. | $30.48 | 2022 | |
| Glaxosmithkline, LLC. | $28.94 | 2025 | Arexvy, Shingrix |
| Merck Sharp & Dohme LLC | $24.00 | 2023 | |
| Mylan Specialty L.P. | $22.20 | 2023 | Yupelri |
| Amgen INC. | $20.64 | 2025 | Repatha |
| Bridgebio Pharma, INC. | $19.97 | 2025 | Attruby |
| Daxor Corporation | $15.39 | 2023 | Bva-100 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.47 | 2023 | Xifaxan |
| Janssen Pharmaceuticals, INC | $13.85 | 2024 | Xarelto |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Maddox listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.